Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

САЩ - английски - NLM (National Library of Medicine)

acrotech biopharma inc - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology (12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology (13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. data   animal data adequate ani

САЩ - английски - NLM (National Library of Medicine)

cenexi - bla - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. history of serious allergic reaction to melphalan. risk summary based on its mechanism of action, evomela can cause fetal harm when administered to a pregnant woman, including teratogenicity and/or embryo-fetal lethality [see clinical pharmacology ( 12.1)] . melphalan is a genotoxic drug and can cause chromatid or chromosome damage in humans [see nonclinical toxicology ( 13.1)] . in animal studies, melphalan was embryolethal and teratogenic in rats at doses below the recommended clinical doses [see data] . advise a pregnant woman of the potential risk to a fetus.. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk in the u.s. general population of major birth def

Белгия - английски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tillomed pharma gmbh - melperone hydrochloride 55,973 mg - eq. melphalan 50 mg - powder and solvent for solution for injection/infusion - 50 mg - melperone hydrochloride 55.973 mg - melphalan

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 50mg - solution for injection - 50 mg - active: melphalan 50mg excipient: hydrochloric acid povidone ethanol propylene glycol sodium citrate dihydrate

Ирландия - английски - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - melphalan - powder and solvent for solution for infusion - 50 milligram(s) - nitrogen mustard analogues; melphalan

Ирландия - английски - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - melphalan - film-coated tablet - 2 milligram(s) - nitrogen mustard analogues; melphalan